Longevity Report · Week of August 8, 2026
Amino acids, resistance dosing, AI health maps, sleep-brain aging, and GLP-1's expanding evidence base
- Valine Restriction Extends Male Mouse Lifespan 23% Through an Unpredicted MechanismTwo facts from the same paper should not be able to coexist, and yet they do.
- The Resistance-Training Dose Question: 90-120 Minutes Weekly and What 137 Studies Actually Show"For people who are less active, the key message is that small amounts can still matter," Edward Giovannucci told Everyday Health in June. "Building a routine gradually may be more important than trying to do a lot at on…
- GLP-1 Beyond Weight Loss: Sorting Cardiovascular Endpoints From Retrospective Cancer SignalsAn incidence rate ratio of 0.87 for major adverse cardiovascular events, drawn from 99,599 patients across 21 randomized trials, graded high-certainty, number-needed-to-treat of 66. That is not a signal. That is an endpo…
- Sleep and Brain Aging: Glymphatic Imaging, Fragmentation Signals, and the Push Toward AI Diagnostics"When we're sleeping, it's like a garbage truck going through our neighborhood and collecting all the garbage cans." That's Duke biomedical engineer Junjie Yao, describing the glymphatic system—the brain's overnight wast…
- Predicting the Health Arc: Harvard's ALADYNOULLI Maps Individual Disease Trajectories Across DecadesHere is the contradiction most readers will miss: the impressive part of ALADYNOULLI is not that it predicts disease better than the calculators we already use. It is that the same machinery driving that accuracy is prec…
Threads we are following
- Whether the male-liver mitochondrial node can be reproduced by a mimetic compound, and why the lifespan effect fails to appear in females
- Whether anyone funds a randomized controlled trial using strength training as the intervention and all-cause mortality as the endpoint.
- Whether prospective randomized trials will confirm or dissolve the GLP-1 breast cancer signal once a metabolic comparator arm is included
- Whether any prospective trial can show that modulating glymphatic function or sleep continuity actually changes an individual's dementia trajectory
- Whether a prospective trial will ever test if signature-informed interventions actually defer or prevent predicted disease, moving ALADYNOULLI from description to clinical lever.
One issue a week. Free.
sift. reads hundreds of sources so you don't have to, and sends one issue you can actually finish. No daily noise. Unsubscribe anytime.